Huazhong University of Science and Technology and affiliated organizations have explored the role of microRNA-218-5p (miR-218-5p) in Parkinson’s disease (PD).

Researchers at Chia Tai Tianqing Pharmaceutical Group Co. Ltd. and Medshine Discovery Inc. have disclosed bicyclic substituted compounds acting as complement factor B (CFB) inhibitors reported to be useful for the treatment of Parkinson's disease.

Korea Institute of Science and Technology has described nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators acting as nitric oxide (NO) production inhibitors and antioxidants reported to be useful for the treatment of acute respiratory distress syndrome, chronic kidney disease, chronic obstructive pulmonary disease, kidney fibrosis, nonalcoholic fatty liver disease, viral hepatitis, Parkinson’s disease and Alzheimer’s disease.

NZP UK Ltd. has divulged 3-azasteroid compounds reported to be useful for the treatment of myalgic encephalomyelitis/chronic fatigue syndrome, acute radiation syndrome and neurodegenerative disorders.

Innovstone Therapeutics Ltd. has synthesized aromatic heterocyclic compounds acting as leucine-rich repeat kinase 2 (LRRK2; Dardarin) inhibitors reported to be useful for the treatment of Parkinson’s disease.

Vandria SA has announced a series A financing round raising $20.6 million (CHF18 million) to help advance its pipeline of first-in-class small-molecule mitophagy inducers.